内分泌科

订阅

MedSci主页 / 所有栏目 / 内分泌科

Diabetes Care：血清黄嘌呤氧化酶活性升高与2型糖尿病发生有关！

2018-02-03 xing.T MedSci原创

黄嘌呤氧化酶2型糖尿病相关
关注

由此可见，血清XO活性升高，而不是UA浓度，与男性和女性发生2型糖尿病的风险增加有关，XO和UA相互调整后。但需要进一步的研究来评估潜在的机制。

近日，糖尿病领域权威杂志Diabetes Care上发表了一篇研究文章，研究人员旨在通过一项大型前瞻性队列研究来评估黄嘌呤氧化酶（XO），尿酸（UA）代谢的关键酶和活性氧簇的主要来源，是否在2型糖尿病（T2DM）的发生发展中起着重要的因果作用。

该研究共涉及4412名在2008年年龄为30-65岁的无糖尿病患者（2071名女性和2341名男性）。参与者平均随访4.7年，主要观察葡萄糖代谢的变化事件。研究人员测定了受试者基线血清XO和尿酸、血脂、血糖稳态指标，包括空腹血糖（FBG）、餐后2小时血糖（PBG）、糖化血红蛋白（HbA1c）、空腹胰岛素。

平均随访4.7年，共有249名女性和360名男性出现新发T2DM。血清XO活性与血UA浓度呈正相关（P＜0.001）。当XO活性和UA浓度在性别特异性分析的相同模型中予以考虑，只有XO活性与T2DM的发生显著相关，XO活性最低四分位数到最高四分位数相比的风险比在妇女受试者中分别为1、1.67（95%可信区间为1-2.79）、1.86（1.11-3.13）和2.36（1.43-3.90）以及在男性受试者中分别为1、1.01（0.68-1.52）、1.41（0.98-2.03）和1.90（1.30-2.78）。

由此可见，血清XO活性升高，而不是UA浓度，与男性和女性发生2型糖尿病的风险增加有关，XO和UA相互调整后。但需要进一步的研究来评估潜在的机制。

原始出处：

Xue Li, et al. Elevated Serum Xanthine Oxidase Activity Is Associated With the Development of Type 2 Diabetes: A Prospective Cohort Study. Diabetes Care 2018. https://doi.org/10.2337/dc17-1434

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1901962, encodeId=0be01901962e2, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Apr 07 15:59:00 CST 2018, time=2018-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822511, encodeId=866a18225115a, content=<a href='/topic/show?id=012c103116b6' target=_blank style='color:#2F92EE;'>#黄嘌呤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103116, encryptionId=012c103116b6, topicName=黄嘌呤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Thu Nov 01 11:59:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638399, encodeId=fbe81638399c9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Dec 10 23:59:00 CST 2018, time=2018-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760519, encodeId=554a1e60519bc, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Mar 19 04:59:00 CST 2018, time=2018-03-19, status=1, ipAttribution=)]
    2018-04-07 木头人513

    #Diabetes#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1901962, encodeId=0be01901962e2, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Apr 07 15:59:00 CST 2018, time=2018-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822511, encodeId=866a18225115a, content=<a href='/topic/show?id=012c103116b6' target=_blank style='color:#2F92EE;'>#黄嘌呤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103116, encryptionId=012c103116b6, topicName=黄嘌呤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Thu Nov 01 11:59:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638399, encodeId=fbe81638399c9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Dec 10 23:59:00 CST 2018, time=2018-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760519, encodeId=554a1e60519bc, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Mar 19 04:59:00 CST 2018, time=2018-03-19, status=1, ipAttribution=)]
    2018-11-01 cenghis

    #黄嘌呤#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1901962, encodeId=0be01901962e2, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Apr 07 15:59:00 CST 2018, time=2018-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822511, encodeId=866a18225115a, content=<a href='/topic/show?id=012c103116b6' target=_blank style='color:#2F92EE;'>#黄嘌呤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103116, encryptionId=012c103116b6, topicName=黄嘌呤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Thu Nov 01 11:59:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638399, encodeId=fbe81638399c9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Dec 10 23:59:00 CST 2018, time=2018-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760519, encodeId=554a1e60519bc, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Mar 19 04:59:00 CST 2018, time=2018-03-19, status=1, ipAttribution=)]
    2018-12-10 ms9608593228839890

    #DIA#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1901962, encodeId=0be01901962e2, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Apr 07 15:59:00 CST 2018, time=2018-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822511, encodeId=866a18225115a, content=<a href='/topic/show?id=012c103116b6' target=_blank style='color:#2F92EE;'>#黄嘌呤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103116, encryptionId=012c103116b6, topicName=黄嘌呤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Thu Nov 01 11:59:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638399, encodeId=fbe81638399c9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Dec 10 23:59:00 CST 2018, time=2018-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760519, encodeId=554a1e60519bc, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Mar 19 04:59:00 CST 2018, time=2018-03-19, status=1, ipAttribution=)]
    2018-03-19 ms5439512287675881

    #BET#

    0

相关资讯

Circulation：黄嘌呤氧化酶抑制剂别嘌呤醇未能改善心衰患者的状况（EXACT-HF研究）

    氧化应激可导致心脏衰竭（HF）的进展。在高尿酸血症HF患者抑制黄嘌呤氧化酶可能提高疗效。    我们随机分配253例有心衰症状，左心室射血分数（LVEF）≤40％，血清尿酸水平≥9.5毫克/分升的患者接受别嘌呤醇（目标剂量，每天600毫克）或安慰剂的双盲，多中心临床试验。在24周的主要复合终点是基于生存，心衰恶化，和病人的全球评估。次要终点包括生活质